NICE publishes final no for Eisai's Halaven
This article was originally published in Scrip
Executive Summary
Today's final guidance from NICE, the health technology appraisal institute for England and Wales, rejects Eisai's Halaven (eribulin) for locally advanced or metastatic breast cancer in patients whose disease has progressed after at least two chemotherapeutic regimens. The rejection comes after a failed appeal from Eisai against the final draft recommendations.